EUVIMEDEUVIMED entdecken
Crossref

Repeat FNA for risk stratification of atypia of undetermined significance in thyroid nodules: A population‐based cohort without molecular testing

Neha Khaitan, Jaleh Esmaeeli, Anita Zamanigohar, Paria Sokhanran, Yung‐Fang Tu, Khashayar Saybani, Lara Maria Stričak, Aland Barzinjy, Karolina Oscilowicz, Ghazal Sokhanran, Christopher C. Griffith, Reza Alaghehbandan

Cancer Cytopathology · 2026-12 · 134 (12)

DOI: 10.1002/cncy.70171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cytopathology, online erschienen am 18.11.2026. Verfasst von Neha Khaitan und 11 weiteren Autor:innen. Die Arbeit nennt 71 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atypia of undetermined significance (AUS; Bethesda category III) is a heterogeneous thyroid fine‐needle aspiration (FNA) category with variable malignancy risk. Molecular testing guides AUS management in North America but is unavailable or cost‐prohibitive in much of the world. This study evaluated repeat FNA as primary AUS triage and the contribution of cytomorphologic subclassification in a population‐based cohort without molecular testing.

Methods

The authors identified all AUS thyroid FNAs in the Fraser Health Authority, British Columbia (2014–2019), with follow‐up through 2022. Index cytology was subclassified by architectural, morphologic/nuclear, and oncocytic atypia. Repeat‐FNA outcomes, surgical pathology, and clinical/radiologic data were correlated; noninvasive follicular thyroid neoplasm with papillary‐like nuclear features was classified as nonmalignant.

Results

Among 611 AUS nodules, 271 (44.4%) underwent repeat FNA and 237 (38.8%) resection. Resection‐based risk of malignancy (ROM) was 32.9% (78 of 237); minimum observed malignancy was 12.8% (78 of 611). The second FNA was benign in 116 (42.8%), persistent AUS in 78 (28.8%), nondiagnostic in 58 (21.4%), and upgraded in 19 (7.0%). Minimum observed malignancy was 2.6% (3 of 116) after a benign versus 47.4% (9 of 19) after an upgraded second FNA. A benign repeat FNA obviated surgery in 103 of 116 (88.8%). AUS‐nuclear carried a higher ROM than AUS‐other (38.6% vs. 21.5%; p = .008; adjusted odds ratio, 2.33; 95% CI, 1.24–4.38) but did not predict repeat‐FNA outcome ( p = .420).

Conclusions

In a molecular‐testing‐free, population‐based cohort, repeat FNA effectively triaged AUS: benign resolution was frequent and marked very low malignancy risk, whereas persistent or upgraded cytology selected nodules for surgery. Cytomorphologic subclassification provided complementary risk stratification, supporting repeat FNA as cost‐effective first‐line management where molecular testing is unavailable.

Zitieren

APA

Khaitan, N., Esmaeeli, J., Zamanigohar, A., Sokhanran, P., Tu, Y., Saybani, K., Stričak, L. M., Barzinjy, A., Oscilowicz, K., Sokhanran, G., Griffith, C. C., & Alaghehbandan, R. (2026). Repeat FNA for risk stratification of atypia of undetermined significance in thyroid nodules: A population‐based cohort without molecular testing. Cancer Cytopathology, 134(12). https://doi.org/10.1002/cncy.70171

Vancouver

Khaitan N, Esmaeeli J, Zamanigohar A, Sokhanran P, Tu Y, Saybani K, et al. Repeat FNA for risk stratification of atypia of undetermined significance in thyroid nodules: A population‐based cohort without molecular testing. Cancer Cytopathology. 2026;134(12). doi:10.1002/cncy.70171

BibTeX
@article{Khaitan2026,
  author = {Khaitan, Neha and Esmaeeli, Jaleh and Zamanigohar, Anita and Sokhanran, Paria and Tu, Yung‐Fang and Saybani, Khashayar and Stričak, Lara Maria and Barzinjy, Aland and Oscilowicz, Karolina and Sokhanran, Ghazal and Griffith, Christopher C. and Alaghehbandan, Reza},
  title = {Repeat FNA for risk stratification of atypia of undetermined significance in thyroid nodules: A population‐based cohort without molecular testing},
  journal = {Cancer Cytopathology},
  year = {2026},
  volume = {134},
  number = {12},
  doi = {10.1002/cncy.70171}
}
Kostenlos starten →